A seasoned biotech investor, led the development of start-up companies to the successful “unicorn” IPO and M&A exits valued at over $3B. Sergei Petukhov is a prominent biotech investor and venture capitalist with over 15 years of experience in the life sciences and healthcare sectors. He is currently the Managing Director at the AMR Action Fund, a global investment fund focused on developing novel antibiotics to combat antimicrobial resistance, with a goal of bringing 2–4 new antibiotics to patients by 2030. 

Previously, he was a Partner at Enso Ventures, where he led biotechnology investments and served on the boards or as board observers for several innovative biotech companies, including Seres Therapeutics, Cavion, Galera Therapeutics, and Cellectar Biosciences. 

He also held leadership roles at CLS Capital and RUSNANO, a Russian nanotechnology investment fund. 

Petukhov holds a DVM (Doctor of Veterinary Medicine) and an MS in Biophysics from the Moscow Academy of Veterinary Medicine and Biotechnology. 

He further studied at The Rockefeller University, University of Edinburgh, and University of Cambridge, and has served as a scientific advisor on pharmaceutical intellectual property litigation at Arnold & Porter Kaye Scholer LLP. 

He is also the Founder of Ludicrous Ventures, a firm focused on advancing innovative medical technologies, and has been involved in various advisory and board roles across the biotech ecosystem. 

His career reflects a deep commitment to translational science, investment in early-stage biotech, and building sustainable innovation in healthcare.